Right before China’s mid-autumn festival, a traditional time to celebrate harvest time, a major deal between a Chinese drug developer and a global pharma giant put the spotlight on the country’s rebounding health market post COVID-19.
Shanghai-based CStone Pharmaceuticals Co. Ltd., an oncology specialist founded four years ago, announced on 29 September a collaboration under...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

